      |
Our Favorite Resources for
-
Dedicated to funding blood cancer research and providing education and patient services.
The Leukemia and Lymphoma Society -
Provides a free information helpline, up-to-date educational materials, peer support, educational programs and financial assistance for patients.
Lymphoma Research Foundation
INFORMATION BY CANCER TYPE
Lymphoma - More Stories
|
Jan 19, 2012 |
|
|
Jan 05, 2012No Need for Maintenance Rituxan in Asymptomatic Follicular Lymphoma Patients who are not suffering from symptoms of nonbulky follicular lymphoma are better off waiting until symptoms occur before beginning chemotherapy instead of undergoing maintenance Rituxan. |
|
|
Jan 05, 2012GA101 Could Upstage Rituxan in Lymphoma GA101 could be the next step for patients who relapse on Rituxan (rituximab), a current standard of therapy. |
|
|
Jan 03, 2012Lymphoma Drug Adcetris Tested in Newly Diagnosed Patients With the approval of Adcetris (brentuximab vedotin) for relapsed Hodgkin lymphoma, researchers are now examining whether the drug will help newly diagnosed patients. |
|
|
Dec 21, 2011Brighter Horizons for Hodgkin Lymphoma Patients The latest advancements in the treatment of Hodgkin lymphoma. |
|
|
Dec 21, 2011Research updates from the annual San Antonio Breast Cancer Symposium and American Society of Hematology. |
|
|
Mar 03, 2011The latest in cancer prevention, diagnosis and treatment. |
|
|
Jan 06, 2011Online Tool Helps Childhood Cancer Survivors Monitor Late Effects Online tool helps cancer survivors know what to look for years after treatment |
|
|
Dec 29, 2010Rituxan May Replace Watch and Wait for Patients with Asymptomatic Follicular Lymphoma Researchers showed that patients with nonsymptomatic, advanced follicular lymphoma (FL) benefit from Rituxan (rituximab) over watchful waiting. |
|
|
Dec 29, 2010Istodax Shows Benefit in T-Cell Lymphomas A phase 2 trial presented at the American Society of Hematology in December could pave the way for a second approval for Istodax (romidepsin). |
